{"name":"Centus Biotherapeutics Limited","slug":"centus-biotherapeutics-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"FKB238 (bevacizumab)","genericName":"FKB238 (bevacizumab)","slug":"fkb238-bevacizumab","indication":"Metastatic colorectal cancer","status":"phase_3"}]}],"pipeline":[{"name":"FKB238 (bevacizumab)","genericName":"FKB238 (bevacizumab)","slug":"fkb238-bevacizumab","phase":"phase_3","mechanism":"FKB238 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.","indications":["Metastatic colorectal cancer","Metastatic non-small cell lung cancer","Metastatic breast cancer","Renal cell carcinoma","Glioblastoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQQzRRaWxaX0Y4TVVjdVdRREgyYjFaVDZRMjJBak1mSGxUdC1WOWV5b0VGUW90RGcyQ05fcXh4RkNyRzdvSmJQMy1fc1M5UmNPWEFGZDlkalJXRmEyYTlvTlpuMWd6RTF0d1JPZzJHY0lZWkE5MjZ5MVpTbzRVOHJnczBR?oc=5","date":"2026-01-22","type":"regulatory","source":"JD Supra","summary":"How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline - Updated January 22, 2026 - JD Supra","headline":"How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline - Updated January 22, 2026","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNRlA3MldGV1BTUTgzeWhyZ0owcGtYeDFRZWprSjZfLVJMZGlOTE9qMU4tNWo5N3ZEajlEVUlIT1M5TlN0b29wVjNUdTM3c2Vpem1aeTFjNS1YVUVEd0g1b0NyalltUGZnbHkxYlV4MC1OWmpFYVRjZExDT3RVOHZOTmNB?oc=5","date":"2025-01-14","type":"regulatory","source":"JD Supra","summary":"How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline - Updated January 13, 2025 - JD Supra","headline":"How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline - Updated January 13, 2025","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE5RckxOb1lQbWJoU0JxRFRHT0JsOUwtNDBySFYzeUZMNEpWM1EyaWxRMW1zLTJxZlczSU5FRzBGajVGbTUzTlFjZExoNVlUQVFQMDdtbGtnWXZjLXRkNGZreEFpelh3dkE0OEE?oc=5","date":"2022-10-04","type":"patent","source":"Wiley Online Library","summary":"Oncology biosimilars: New developments and future directions - Bachu - 2022 - Cancer Reports - Wiley Online Library","headline":"Oncology biosimilars: New developments and future directions - Bachu - 2022 - Cancer Reports","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}